Short answer
Kymera Therapeutics, Inc. (KYMR) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 8.01 (Other Events). ATM equity offering up to $500M via TD Cowen, sold opportunistically on Nasdaq at Company's discretion.
Kymera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- ATM equity offering up to $500M via TD Cowen, sold opportunistically on Nasdaq at Company's discretion
- TD Cowen earns up to 3.0% commission on gross proceeds: no obligation to sell any minimum amount
- Potential dilution risk: $500M in new shares could be issued at any time without further shareholder approval
- Shelf registration (Form S-3ASR filed Oct 2024) already effective, enabling rapid capital deployment with no additional SEC review delay
Item 1.02 · Termination of a Material Definitive Agreement
- ATM equity offering program with Jefferies terminated immediately effective February 26, 2026
- Removal of at-the-money sales channel signals company may no longer need opportunistic equity raises via open market
- Investors should watch for alternative financing announcements or indication current cash runway is sufficient without ATM dilution
Item 8.01 · Other Events
- Resale registration covers up to 18.8M common shares + 12.6M pre-funded warrant shares (~31.4M total shares eligible for market sale
- Selling stockholders: Baker Brothers, 667 L.P., Atlas Venture, BVF Partners; all institutional insiders from June 2025 registration rights agreement
- Company receives no proceeds from share resales; minimal proceeds only if warrants exercised for cash at $0.0001/share
- Registration ≠ immediate sale: but unlocks significant potential supply overhang (~31.4M shares) that could pressure stock price
- No new dilution to existing shareholders; these are already-issued shares being registered for resale
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kymera Therapeutics, Inc. 8-K filings
Get the next KYMR 8-K as it lands
Follow KYMR for push alerts, or ask the research agent what this filing means.